Free Mesothelioma Information Packet

Pasi A. Janne M.D.

  • Associate Professor of Medicine
  • Harvard University Medical School
  • 617-632-6049

Pasi A. Janne has a Medical Degree and PhD from the University of Pennsylvania, where he graduated in 1996. He continued his medical training at Brigham and Women’s Hospital focusing on internal medicine. He also trained in medical oncology at the Dana Farber Cancer Institute. Currently he works in the Lowe Center for Thoracic Oncology at the Dana Farber Cancer Institute and is an Assistant Professor of Medicine at Harvard Medical School. Dr. Janne’s main interest is the study of epidermal growth factor receptor mutations in non-small cell lung cancer and their impact on the efficacy of epidermal growth factor receptor-targeted therapeutics agents.

Dr. Janne’s main research focuses on the epidermal growth factor receptor. He has done several studies with this and has concluded that only gefitinib (Iressa) killed lung cancer cells containing the epidermal growth factor receptor. He has also studied how the drug, Tarceva, tyrosine kinase inhibitor erlotinib, helps older lung cancer patients. Dr. Janne is also interested in more innovative approaches to treating mesothelioma such as photodynamic therapy, which would follow a pleurectomy/decortication and would help in the early stage of the disease. Immunotherapy is another such innovative approach, which uses cytokines to enhance the immune system anti-tumor response. The interferon gamma (Actimmune) is the most promising immunotherapy drug as of now. Gene Therapy, which uses viruses to transfer genetic material into either immune or tumor cells to alter biological activity, is another innovative approach towards treating mesothelioma. In this instance the use of Adenoviruses, such as the herpes simplex virus, thymindine kinase gene, would be used. Another approach is the intracatvity heated chemotherapy which uses higher local drug concentrations with the lowest systemic toxicity. Thus hyperthermia and cisplatin are administered systemically.

References:
  • Harvard University Medical School. Faculty Profile.

Last modified: December 24, 2010.